Gilead Sciences Given Average Recommendation of “Buy” by Analysts (NASDAQ:GILD)
Shares of Gilead Sciences (NASDAQ:GILD) have been given an average rating of “Buy” by the twenty-six ratings firms that are presently covering the stock, StockRatingsNetwork reports. One investment analyst has rated the stock with a hold recommendation and twenty-one have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $105.05.
Gilead Sciences (NASDAQ:GILD) opened at 100.20 on Tuesday. Gilead Sciences has a 52-week low of $56.75 and a 52-week high of $101.50. The stock’s 50-day moving average is $90. and its 200-day moving average is $81.39. The company has a market cap of $151.5 billion and a P/E ratio of 22.82.
Gilead Sciences (NASDAQ:GILD) last released its earnings data on Wednesday, July 23rd. The company reported $2.36 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.73 by $0.63. The company had revenue of $6.53 billion for the quarter, compared to the consensus estimate of $5.68 billion. During the same quarter in the prior year, the company posted $0.50 earnings per share. The company’s quarterly revenue was up 136.1% on a year-over-year basis. Analysts expect that Gilead Sciences will post $8.00 EPS for the current fiscal year.
In other Gilead Sciences news, CFO Robin L. Washington sold 33,556 shares of the stock in a transaction that occurred on Thursday, August 14th. The stock was sold at an average price of $95.56, for a total value of $3,206,611.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
A number of research firms have recently commented on GILD. Analysts at Cowen and Company raised their price target on shares of Gilead Sciences from $95.00 to $105.00 in a research note on Friday. They now have an “outperform” rating on the stock. Separately, analysts at RBC Capital initiated coverage on shares of Gilead Sciences in a research note on Friday. They set an “outperform” rating on the stock. Finally, analysts at FBR Capital Markets initiated coverage on shares of Gilead Sciences in a research note on Thursday, August 14th. They set an “outperform” rating and a $125.00 price target on the stock.
Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.